Difference between revisions of "NextGen-O2k H2020 SME Phase 1"

Revision as of 15:21, 7 August 2018

NextGen-O2k H2020 SME Phase 1

A project in progress

Horizon2020 SME Instrument

NextGen-O2k has successfully reached and accomplished Phase 1 of the two-step Horizon2020 SME funding instrument.
Project duration: 2018-02-01 to 2018-05-31.
Funding: € 50,000.

Project Output

The aim of the Phase 1 project was to generate a feasibility study for the development and market launch of the NextGen-O2k and the Q2k. This study consists of a technical plan, a commercial plan and a financial plan and considers technical risks, competition, market conditions and IP rights for a go or no-go decision for the NextGen project:

The analysis reveals that we have a strong project from all angles:

Technically: The project is technically feasible, and we have the required expertise, own personnel and will

team up with experienced subcontractors to develop it. In addition, thanks to the expertise and knowledge gained from the development and commercialization of previous products of the company, like the O2k- FluoroRespirometer and its add-on modules we have already defined the needed steps to optimise our new device together with a thorough risk analysis and mitigation/contingency plan.

Commercially: There is a clear unmet need within our target market, as there are currently no research

instruments for mitochondrial investigation that provide an in-depth view of the functional mitochondrial state. Our analysis demonstrates that our target markets will show a constant growth driven by current research trends and the new discoveries of the implication of mitochondria in a wide range of diseases (diabetes, cancer, obesity or neurodegenerative diseases). The Global life science instrumentation market in basic research, healthcare and medical applications is likely to reach $75.24 Billion by 2022, growing at a CAGR of 6.7% from 2017 to 2022. This promising scenario represents a unique opportunity for us.

Financially: Our financial analysis has demonstrated the economic feasibility of our project, with precisely

calculated production costs, which are realistic and in-line with those defined by the actual market situation. Our forecast shows that our business can have a relevant economic impact, enabling us to achieve €46.7 million revenues and €18 million of cumulative net income by 2025, with an ROI of 3.5.

GO DECISION: Based on all the above-mentioned reasons, we have decided to go ahead with the herein presented project plan

@@ Line 11: / Line 11: @@
 == Project Output ==
-The aim of the Phase 1 project was to generate a feasibility study (including a market study and a financial forecast) for the development and market launch of the NextGen-O2k and the Q2k. The freedom-to-operate (FTO) analysis that was carried out in the course of the feasibility study resulted in the following statement:
+The aim of the Phase 1 project was to generate a feasibility study for the development and market launch of the NextGen-O2k and the Q2k. This study consists of a technical plan, a commercial plan and a financial plan and considers technical risks, competition, market conditions and IP rights for a go or no-go decision for the NextGen project:
-"FREEDOM-TO-OPERATE: After careful analysis of these patents identified through Patent Inspiration, we
-conclude that we have not found any patent that overlaps with NextGen-O2k innovative properties. The
+The analysis reveals that we have a strong project from all angles:
-combination of sensors used by us is absolutely unique and, moreover, there is no a single device that includes
+::::* Technically: The project is technically feasible, and we have the required expertise, own personnel and will
-the Q-sensor for coenzyme Q redox state. Therefore, we have full freedom-to-operate."
+team up with experienced subcontractors to develop it. In addition, thanks to the expertise and knowledge
+gained from the development and commercialization of previous products of the company, like the O2k-
+FluoroRespirometer and its add-on modules we have already defined the needed steps to optimise our new
+device together with a thorough risk analysis and mitigation/contingency plan.
+::::* Commercially: There is a clear unmet need within our target market, as there are currently no research
+instruments for mitochondrial investigation that provide an in-depth view of the functional mitochondrial
+state. Our analysis demonstrates that our target markets will show a constant growth driven by current research
+trends and the new discoveries of the implication of mitochondria in a wide range of diseases (diabetes, cancer,
+obesity or neurodegenerative diseases). The Global life science instrumentation market in basic research,
+healthcare and medical applications is likely to reach $75.24 Billion by 2022, growing at a CAGR of 6.7% from 2017
+to 2022. This promising scenario represents a unique opportunity for us.
+::::* Financially: Our financial analysis has demonstrated the economic feasibility of our project, with precisely
+calculated production costs, which are realistic and in-line with those defined by the actual market situation. Our
+forecast shows that our business can have a relevant economic impact, enabling us to achieve €46.7 million
+revenues and €18 million of cumulative net income by 2025, with an ROI of 3.5.
+GO DECISION: Based on all the above-mentioned reasons, we have decided to go ahead with the herein
+presented project plan